Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001867096-25-000136
Filing Date
2025-08-07
Accepted
2025-08-07 16:45:55
Documents
78
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q xers-20250630.htm   iXBRL 10-Q 1022920
2 EX-31.1 a2025q210-qexhibit311.htm EX-31.1 9936
3 EX-31.2 a2025q210-qexhibit312.htm EX-31.2 9871
4 EX-32.1 a2025q210-qexhibit321.htm EX-32.1 7821
  Complete submission text file 0001867096-25-000136.txt   6118959

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20250630.xsd EX-101.SCH 45211
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xers-20250630_cal.xml EX-101.CAL 74086
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20250630_def.xml EX-101.DEF 211268
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20250630_lab.xml EX-101.LAB 616947
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20250630_pre.xml EX-101.PRE 423221
81 EXTRACTED XBRL INSTANCE DOCUMENT xers-20250630_htm.xml XML 730359
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

EIN.: 871082097 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40880 | Film No.: 251194938
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)